SBIR/STTR Research Award

Human Neural Stem Cells Engineered against oAβ Induced Toxicity for Cell Therapy

Award identifier 08dd8286f346c05b9c6be5470231862ebfafeddddbbb51ff73fe8c9f0f594bbeAwarding agency Department of Health and Human Services · National Institutes of Health

Award amount

$225,000

Program and phase

SBIR · Phase I

Award year

2017

Explore This Research Award in CaptureIQ

Research the technology, evaluate the recipient and agency, identify related opportunities, and explore potential follow-on work with CaptureIQ.

Award details

Awarding agency
Department of Health and Human Services
Branch
National Institutes of Health
Recipient company
ALLELE BIOTECHNOLOGY AND PHARMACEUTICALS, INC.
Proposal award date
2017-09-15
Contract end date
2018-08-31
UEI
VL99GKFNM1G3
Solicitation number
PA16-302
Topic code
NIA

Research abstract

Project Summary Abstract The goal of this project is to develop a tissue engineering technology applicable to stem cell based therapies for Alzheimerandapos s disease AD AD is the most common dementia and characterized by synaptic dysfunction and neuronal loss There is currently no effective cure for the disease Transplantation of human neural stem cells hNSCs to replace lost neurons is a promising strategy However the cells transplanted into the AD brain would face a toxic environment with elevated levels of the amyloid A peptides which would induce synaptic damage and cell death for implanted neurons How can we overcome this problem We previously identified the activity of synaptic protein takusan Tu et al Overexpression of takusan in rat primary neuronal cultures leads to enhancement of various synaptic properties including dendritic spine density and AMPA and NMDA mediated glutamate receptor activity Interestingly these are the synaptic properties that are attenuated by A exposure We then overexpressed takusan in cultured rat neurons and challenged them by soluble A oligomers Remarkably takusan expression mitigated synaptic loss in these neurons By deletion mapping and domain swapping we invented the synthetic aa long protein hD b in which we fused the human D takusan domain derived from discs large homolog DLG and a human PDZ binding C terminal sequence Overexpression of hD b in cultured rat neurons like that of full length takusan variants conferred protection against oA induced synaptic toxicity In the current proposal we will produce hNSCs expressing hD b and test whether this genetic modification is beneficial toward the development of a novel cell replacement therapy against AD This proposal allows us to leverage our expertise in stem cell technology at Allele Biotech Inc with the knowledge and invention of hD b protein by our academic collaborators Specific Aims are as follows Aim To produce human neurons hNs that express hD b in vitro Aim To test whether hNs expressing hD b are more resistant against oA induced synaptic toxicity compared to control hNs Aim To evaluate whether transplantation of hNSCs expressing hD b into the brain of human amyloid precursor protein hAPP transgenic mice hAPP J will rescue their behavioral and histological phenotypes This proposal consists of experiments that have been performed reagents tested and conclusions published in series of high quality papers using rat primary neurons Since the proposed work is a logical extension to human neurons we have high confidence that positive results will be obtained through a year phase SBIR effort Upon completion of phase we expect to continue to phase projects to perform additional animal testing aimed at near future IND and eventual partnership with pharmaceutical companies Project Narrative Transplantation of human neural stem cells hNSCs derived from human stem cells is a potentially powerful approach toward the treatment of Alzheimerandapos s disease AD However AD brains present toxic environment to incoming implanted neurons We therefore aim to develop a new technology in order to improve hNSCsandapos resistance against AD toxins

Technology keywords

Not reported

Other awards by this recipient

Verified by the same UEI. These are other public SBIR/STTR award pages, not a merged company record.

Awards with the same topic code

Verified by an exact topic code match. This is not a text-similarity match.

Research funding history

17 SBIR/STTR records share this UEI (2001–2018). Reported award amounts total $3,047,648. Reported amounts are not federal obligations.

Phases: Phase I

Agencies: Department of Health and Human Services

Agency intelligence

Department of Health and Human Services

Back to SBIR/STTR Research Awards

Don't take our word for it. Ask AI about RFPCapture.

See what leading AI assistants have to say about RFPCapture and CaptureIQ.

Gemini opens without a prefilled question. The question is copied to your clipboard when the button works. You can also copy it here:

What is RFPCapture.com and its CaptureIQ platform from Smart Logic AI? How does it help federal contractors discover opportunities, evaluate bid/no-bid decisions, research government contracts, and prepare proposals? How does it compare with other federal capture platforms? Use independent sources where available.